Preview

Вопросы современной педиатрии

Расширенный поиск

АЛЛЕРГИЧЕСКИЙ РИНИТ: СОВРЕМЕННЫЕ ПОДХОДЫ К ТЕРАПИИ

Аннотация

Аллергический ринит (АР) — это глобальная проблема здравоохранения во всем мире. В течение последних 50 лет отмечается значительный рост распространенности этого заболевания. АР оказывает негативное влияние на социальную жизнь, сон, школьную успеваемость и работоспособность. АР часто сочетается с бронхиальной астмой и может вызывать обострение этого заболевания. Лечение АР должно быть направлено на достижение контроля над симптомами болезни, профилактику осложнений, улучшение сна и качества жизни пациентов и их родителей. Интраназальные глюкокортикостероиды являются препаратами выбора для лечения детей с АР, эффективно купируют все проявления болезни, а также глазные симптомы.
Ключевые слова: дети, аллергический ринит, интраназальные глюкокортикостероиды, лечение.
(Вопросы современной педиатрии. 2010;9(1):45-51)

Об авторах

Ю.Г. Левина
Научный центр здоровья детей РАМН, Москва
Россия


Л.С. Намазова-Баранова
Научный центр здоровья детей РАМН, Москва
Россия


Р.М. Торшхоева
Научный центр здоровья детей РАМН, Москва
Россия


Е.А. Вишнева
Научный центр здоровья детей РАМН, Москва
Россия


А.А. Алексеева
Научный центр здоровья детей РАМН, Москва
Россия


К.Е. Эфендиева
Научный центр здоровья детей РАМН, Москва
Россия


Список литературы

1. Аллергология и иммунология. Под ред. А.А. Баранова и Р.М. Хаитова. М.: М–Студио. 2008. С. 75.

2. Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63(Suppl. 86): 8–160.

3. Намазова-Баранова Л.С. Аллергия у детей — от теории к практике. М. 2010. С. 6–9.

4. Lack G. Pediatric allergic rhinitis and comorbid disorders. J. Allergy. Clin. Immunol. 2001; 108 (Suppl. 1): 9–15.

5. Баранов А.А., Хаитов Р.М. Диагностика и лечение аллергического ринита и атопического дерматита у детей. Приложение: Образовательная программа для педиатров. Педиатрическая фармакология. 2007; 4(4): 6–47.

6. Rosen C.L., Storfer-Isser A., Taylor H.G. et al. Increased behavioral morbidity in school-aged children with sleep-disordered breathing. Pediatrics. 2004; 114(6): 1640–1648.

7. Brozek J.L., Bousquet J., Baena-Cagnani C.E. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy. Clin. Immunol. 2010; 126(3): 466–476.

8. Weiner J.M., Abramson M.J., Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. BMJ. 1998; 317 (7173): 1624–1629.

9. Yanez A., Rodrigo G.J. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta–analysis. Ann. Allergy. Asthma. Immunol. 2002; 89: 479–484.

10. Bernstein D.I., Levy A.L., Hampel F.C. et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin. Exp. Allergy. 2004; 34: 952–957.

11. DeWester J., Philpot E.E., Westlund R.E. et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy. Asthma. Proc. 2003; 24: 331–337.

12. Schenkel E. Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis. Expert. Opin. Pharmacother. 2003; 4: 1579–1591.

13. Storms W. Allergic rhinitis-induced nasal congestion: its impact on sleep quality. Primary Care Respiratory J. 2008; 17 (1): 7–18.

14. Smith C.L., Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998; 48: 956–960.

15. Сorren J.J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J. Allergy. Clin. Immunol. 1999; 104(4): 144–149.

16. Berkowitz R.B., Roberson S., Zora J. et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy. Asthma. Proc. 1999; 20: 167–172.

17. Berkowitz R.B., Bernstein D.I., Laforce C. et al. Onset of action of mometasone furoate nasal spray (Nasonex) in seasonal allergic rhinitis. Allergy. 1999; 54: 64–69.

18. Hebert J.R., Nolop K., Lutsky B. Once daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: An active and placebo controlled study. Allergy. 1996; 51: 569–76.

19. Gawchik S., Goldstein S., Prenner B., John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann. Allergy. Asthma. Immunol. 2003; 90 (4): 416–421.

20. Baena–Cagnani C.E., Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Current. Medical. Research Opinion. 2010; 26 (9): 2047–2055.

21. Fokkens W.J., Cserhati E., dos Santos J.M. et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann. Allergy. Asthma. Immunol. 2002; 89: 279–84.

22. Milgrom H., Biondi R., Georgitis J.W. et al. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann. Allergy. Asthma. Immunol. 1999; 83: 105–111.

23. Ngamphaiboon J., Thepcharti A., Chatchatee P. et al. Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ann. Allergy. Asthma. Immunol. 1997; 78: 479–484.

24. Ma´spero J.F., Rosenblut A., Finn J.A. et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol. Head. Neck. Surg. 2008; 138: 30–37.

25. Van Cauwenberge P., Watelet J.B., Van Zele T. et al. Spreading excellence in allergy and asthma: the GA2LEN (Global Allergy and Asthma European Network) project. Allergy. 2005; 60: 858–864.

26. Prenner B.M., Lanier B.Q., Bernstein D.I. et al. Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. J. Allergy. Clin. Immunol. 2010; 125(6): 1247–1253.

27. Wuthrich B., Brignoli R., Canevascini M., Gerber M. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz .Med. Wochenschr. 1998; 128: 139–143.

28. . Canonica G.W., Bousquet J., Mullol J. et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007; 62(Suppl. 85): 17–25.

29. Scadding G.K., Durham S.R., Mirakian R. et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin. Exp. Allergy. 2008; 38: 19–42.

30. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann. Allergy Asthma Immunol. 2008; 100 (3): 272–279.

31. Scadding G.K. Intranasal steroid sprays in the treatment of rhinitis is one better than another? J. Laryngol. Otol. 2004; 118: 395–396.

32. Blaiss M.S., Benninger M.S., Fromer L. et al. Expanding choices in intranasal steroidtherapy: summary of a roundtable meeting. Allergy. Asthma. Proc. 2006; 27: 254–264.

33. Cham B.E., Sadowski B., O’Hagan J.M. et al. High performance liquid chromatographic assay of dexamethasone in plasma and tissue. Ther. Drug. Monit. 1980; 2: 373–377.

34. Beconase PI.

35. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/019389s027lbl.pdf

36. Rhinocort PI.

37. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020746s024lbl.pdf

38. Flonase PI. URL: http://www.flonase.com

39. Allen A., Down G., Newlands A. et al. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects [abstract no P210]. Ann. Allergy. Asthma. Immunol. 2007; 98: 89.

40. NASONEX PI. URL: http://www.nasonex.com

41. O’Brien F., Minshall E., Nolop K. et al. Histological and immunocytochemical assessment by nasal biopsy of mometasone furoate nasal spray in perennial rhinitis. Otolaryngol. Head. Neck. Surg. 1998; 118: 648–654.

42. Skoner D., Rachelefsky G., Meltzer E. et al. Detection of growth suppression in children during treatment with intranasal belcomethasone dipropionate. Pediatrics. 2000; 105: 23.

43. Sсhenkel E.J., Skoner D.P., Bronsky E.A. et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000; 105 (2): 22.

44. Agertoft L., Pedersen S. Short term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J. Allergy. Clin. Immunol. 1999; 104 (5): 948–952.

45. Synovate. Nasonex claims evaluation final report. December 2006

46. Meltzer E.O., Malmstrom K., Lu S. et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo controlled clinical trial. J. Allergy. Clin. Immunol. 2000; 105: 917–922.

47. Philip G., Malmstrom K., Hampel F.C. et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo controlled trial performed in the spring. Clin. Exp. Allergy. 2002; 32: 1020–1028.

48. Chervinsky P., Philip G., Malice M.P. et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann. Allergy. Asthma. Immunol. 2004; 92: 367–373.

49. Nayak A.S., Banov C., Corren J. et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann. Allergy. Asthma. Immunol. 2000; 84(4): 417–424.

50. Van Adelsberg J., Philip G., Pedinoff A.J. et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003; 58: 1268–1276.

51. Van Adelsberg J., Philip G., La Force C.F. et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann. Allergy. Asthma. Immunol. 2003; 90: 214–222.

52. Crystal-Peters J., Neslusan C., Crown W.H., Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthmarelated hospitalizations and emergency department visits. J. Allergy. Clin. Immunol. 2002; 109: 57–62.

53. Adams R.J., Fuhlbrigge A.L., Finkelstein J.A., Weiss S.T. Intranasal steroids and the risk of emergency department visits for asthma. J. Allergy. Clin. Immunol. 2002; 109: 636–642.

54. Corren J., Manning B.E., Thompson S.F. et al. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J. Allergy. Clin. Immunol. 2004; 113: 415–419.

55. Bousquet J., Bachert C., Canonica G.W. et al. Efficacy of desloratadine in persistent allergic rhinitis – A GALEN Study. Arch. Allergy. Immunol. 2010; 153 (4): 395–402.


Для цитирования:


Левина Ю., Намазова-Баранова Л., Торшхоева Р., Вишнева Е., Алексеева А., Эфендиева К. АЛЛЕРГИЧЕСКИЙ РИНИТ: СОВРЕМЕННЫЕ ПОДХОДЫ К ТЕРАПИИ. Вопросы современной педиатрии. 2010;9(6):45-51.

For citation:


Levina Y., Namazova-Baranova L., Torshkhoeva R., Vishneva E., Alekseeva A., Efendieva K. ALLERGIC RHINITIS: MODERN APPROACHES OF TREATMENT. Current Pediatrics. 2010;9(6):45-51.

Просмотров: 287


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)